Mersana Therapeutics Shares Climb 23% After 3Q Results Beat Estimates

Dow Jones11-14

By Kailyn Rhone

Shares of Mersana Therapeutics jumped Wednesday after the company's loss narrowed and its third-quarter results topped analysts' expectations.

The stock was up 23% to $2.71 in morning trading. For the year, shares are up 16%.

The biopharmaceutical company posted a loss of $11.5 million, or nine cents a share, compared with a loss of $41.7 million, or 35 cents a share, a year earlier. Analysts polled by FactSet had expected a loss of 17 cents.

The Cambridge, Mass.-based company's revenue rose to $12.6 million from $7.7 million the prior year, above analysts expectations of $7.5 million.

Mersana's cash, cash equivalents and marketable securities were $155.2 million as of Sept. 30. The company expects its capital resources will be sufficient to support its operations through 2026.

Write to Kailyn Rhone at kailyn.rhone@wsj.com

(END) Dow Jones Newswires

November 13, 2024 11:30 ET (16:30 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483836484?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-14 00:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483836484","market":"fut","top_or_hot":-1,"title":"Mersana Therapeutics Shares Climb 23% After 3Q Results Beat Estimates","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Kailyn Rhone \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Mersana <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> jumped Wednesday after the company's loss narrowed and its third-quarter results topped analysts' expectations. \n</p>\n<p>\n  The stock was up 23% to $2.71 in morning trading. For the year, shares are up 16%. \n</p>\n<p>\n  The biopharmaceutical company posted a loss of $11.5 million, or nine cents a share, compared with a loss of $41.7 million, or 35 cents a share, a year earlier. Analysts polled by FactSet had expected a loss of 17 cents. \n</p>\n<p>\n  The Cambridge, Mass.-based company's revenue rose to $12.6 million from $7.7 million the prior year, above analysts expectations of $7.5 million. \n</p>\n<p>\n  Mersana's cash, cash equivalents and marketable securities were $155.2 million as of Sept. 30. The company expects its capital resources will be sufficient to support its operations through 2026. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Kailyn Rhone at kailyn.rhone@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 13, 2024 11:30 ET (16:30 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mersana Therapeutics Shares Climb 23% After 3Q Results Beat Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMersana Therapeutics Shares Climb 23% After 3Q Results Beat Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-14 00:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Kailyn Rhone \n\n\n \n\n\n  Shares of Mersana Therapeutics jumped Wednesday after the company's loss narrowed and its third-quarter results topped analysts' expectations. \n\n\n  The stock was up 23% to $...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4563","symbol_name":"昨日强势股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2483836484","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483836484","pubTimestamp":1731515400,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Mersana Therapeutics jumped Wednesday after the company's loss narrowed and its third-quarter results topped analysts' expectations.The stock was up 23% to $2.71 in morning trading. For the year, shares are up 16%.The biopharmaceutical company posted a loss of $11.5 million, or nine cents a share, compared with a loss of $41.7 million, or 35 cents a share, a year earlier. Analysts polled by FactSet had expected a loss of 17 cents.The Cambridge, Mass.-based company's revenue rose to $12.6 million from $7.7 million the prior year, above analysts expectations of $7.5 million.Mersana's cash, cash equivalents and marketable securities were $155.2 million as of Sept. 30. The company expects its capital resources will be sufficient to support its operations through 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4563":"昨日强势股","BK4139":"生物科技","MRSN":"Mersana Therapeutics Inc.","LENZ":"Therapeutics"},"translate_title":"第三季度业绩超出预期后，Mersana Therapeutics股价上涨23%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"MRSN":0.9},"content_text":"By Kailyn Rhone \n\n\n \n\n\n  Shares of Mersana Therapeutics jumped Wednesday after the company's loss narrowed and its third-quarter results topped analysts' expectations. \n\n\n  The stock was up 23% to $2.71 in morning trading. For the year, shares are up 16%. \n\n\n  The biopharmaceutical company posted a loss of $11.5 million, or nine cents a share, compared with a loss of $41.7 million, or 35 cents a share, a year earlier. Analysts polled by FactSet had expected a loss of 17 cents. \n\n\n  The Cambridge, Mass.-based company's revenue rose to $12.6 million from $7.7 million the prior year, above analysts expectations of $7.5 million. \n\n\n  Mersana's cash, cash equivalents and marketable securities were $155.2 million as of Sept. 30. The company expects its capital resources will be sufficient to support its operations through 2026. \n\n\n \n\n\n  Write to Kailyn Rhone at kailyn.rhone@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2024 11:30 ET (16:30 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483836484"}